Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Subscribe to Free Drug Patent Expiration Updates

Also available in a Drug Patent Expiration NewsletterRSS feed and on Drug Patent Expirations on TwitterTwitter

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: ZELNORM

« Back to Dashboard
Zelnorm is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in ZELNORM is tegaserod maleate. Additional details are available on the tegaserod maleate profile page.

Summary for Tradename: ZELNORM


Clinical Trials for: ZELNORM

A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation
Status: No longer available Condition: Irritable Bowel Syndrome With Constipation; Chronic Idiopathic Constipation

Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis
Status: Terminated Condition: Gastroparesis; Diabetes

The Effects of Tegaserod Vs. Placebo on Whole Gut Transit Time in Patients With Chronic Constipation and Dyspepsia
Status: Withdrawn Condition: Constipation and Dyspepsia

Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.
Status: Terminated Condition: Opioid-induced Constipation

Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.
Status: Terminated Condition: Opioid-induced Constipation

The Effects of Tegaserod on Mechanical Sensitivity of the Esophagus and Stomach in Patients With Heartburn and Dyspepsia.
Status: Completed Condition: Heartburn; Dyspepsia

Preference of Tegaserod vs. PEG 3350 in Patients With Constipation
Status: Completed Condition: Constipation

The Role of Tegaserod Therapy in the Management of Dyspeptic Symptoms in Female Patients on Proton Pump Inhibitors for the Treatment of Heartburn.
Status: Completed Condition: Dyspepsia

Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).
Status: Completed Condition: Gastroesophageal Reflux Disease (GERD)

An Evaluation of the Efficacy and Safety of Tegaserod 6 mg Bid Given Orally to Chinese Patients With Chronic Constipation
Status: Completed Condition: Constipation

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
tegaserod maleate
TABLET;ORAL021200-001Jul 24, 2002DISCNNo<disabled><disabled>
tegaserod maleate
TABLET;ORAL021200-002Jul 24, 2002DISCNNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn